RDY — Dr. Reddy's Laboratories Ltd

Is RDY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Overbought As of November 17, 2026

Dr. Reddy's Laboratories Ltd (RDY) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $14.70. The rating moved from Neutral to Overbought on November 17, 2026.

See all overbought Healthcare stocks →

AI analysis

Dr. Reddy's benefits from a diversified product mix, established manufacturing and incremental upside from specialty/biosimilar initiatives, which together provide steady cashflow and downside protection in cautious markets. Near-term performance will hinge on generics pricing dynamics in the U.S., execution on specialty programs, and operational resilience through regulatory inspections and FX movements. Social and news signals are neutral-to-muted, with limited company-specific catalysts in the immediate window. Key scenarios include stable execution with modest upside if specialty uptake and ANDA approvals progress, or downside pressure if pricing erosion, inspection issues or adverse currency moves accelerate.

Key factors

  • Diversified product portfolio across generics, OTC, active pharmaceutical ingredients and specialty medicines provides revenue resilience across geographies
  • Established manufacturing footprint and regulatory approvals in multiple markets support stable supply and commercial access
  • Selective specialty and biosimilar initiatives offer incremental higher‑margin growth optionality versus pure generics exposure
  • Defensive sector flows into large-cap pharma and healthcare reduce downside from broad market risk-off in the near term
  • Reasonable near-term visibility from existing ANDA pipeline and contract manufacturing relationships

Risks

  • Intense pricing pressure and margin compression in the U.S. generics market due to competition and consolidation among buyers
  • Regulatory, quality or inspection issues that can disrupt shipments and trigger recalls or plant shutdowns
  • Currency volatility (INR vs USD) and commodity inflation that can weigh on reported earnings and margins
  • Exposure to patent litigation outcomes and generic erosion for key products
  • Geopolitical or trade disruptions impacting API supply chains and export markets
  • Potential negative readthroughs from U.S. healthcare policy or payor reimbursement changes that affect demand or pricing

See today's live rating, score and targets

Members see the live hourly rating for RDY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.